Journey Medical (NASDAQ:DERM) Posts Earnings Results, Beats Estimates By $0.30 EPS

Journey Medical (NASDAQ:DERM - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.30, Zacks reports. The business had revenue of $14.30 million for the quarter, compared to analysts' expectations of $14.21 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%.

Journey Medical Price Performance

Shares of DERM traded up $0.04 during midday trading on Tuesday, hitting $5.94. 21,837 shares of the company traded hands, compared to its average volume of 86,029. The stock has a 50-day moving average of $5.14 and a 200-day moving average of $5.18. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. Journey Medical has a one year low of $3.20 and a one year high of $6.89. The firm has a market cap of $124.00 million, a P/E ratio of -6.32 and a beta of 0.97.

Insider Activity

In related news, CEO Claude Maraoui sold 49,271 shares of Journey Medical stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total transaction of $246,847.71. Following the completion of the sale, the chief executive officer now owns 2,003,147 shares of the company's stock, valued at approximately $10,035,766.47. This trade represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 105,831 shares of company stock worth $536,622 in the last three months. Corporate insiders own 13.16% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Separately, Alliance Global Partners restated a "buy" rating on shares of Journey Medical in a research note on Thursday, March 27th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $9.67.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.